Publications

• Discovery of Gene Fusions in Driver-Negative Cancer Samples From the National Cancer Institute-Molecular Analysis for Therapy Choice Screening Cohort.Kaluziak ST, Codd EM, Purohit R, Melli B, Kalyan P, Fordham JA, Kirkpatrick G, McShane LM, Chang TC, Yang G, Wang J, Williams PM, Karlovich C, Sklar J, Iafrate AJ. JCO Precis Oncol. 2024 Dec; 2024 Dec 5. PMID: 39637335.
• NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J. Br J Cancer. 2024 Feb; 2023 Dec 22. PMID: 38135713.
• Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.Cecchini M, Zhang JY, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein SM, Kortmansky J, Johung KL, Bindra RS, LoRusso P, Schalper KA. Cancer Res Commun. 2023 Jun; 2023 Jun 28. PMID: 37387791.
• The NCI-MATCH trial: lessons for precision oncology.O'Dwyer PJ, Gray RJ, Flaherty KT, Chen AP, Li S, Wang V, McShane LM, Patton DR, Tricoli JV, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Rubinstein LV, Little RF, Arteaga CL, Marinucci D, Hamilton SR, Conley BA, Harris LN, Doroshow JH. Nat Med. 2023 Jun; 2023 Jun 15. PMID: 37322121.
• Deletion of Jazf1 gene causes early growth retardation and insulin resistance in mice.Lee HY, Jang HR, Li H, Samuel VT, Dudek KD, Osipovich AB, Magnuson MA, Sklar J, Shulman GI. Proc Natl Acad Sci U S A. 2022 Dec 6; 2022 Nov 28. PMID: 36442127.
• Glycemic variability and indices of glycemic control among pregnant women with type 1 diabetes (T1D) based on the use of continuous glucose monitoring share technology.Sklar J, Pyle L, Snell-Bergeon JK, Garcetti R, Joshee P, Demmitt JK, Polsky S. J Matern Fetal Neonatal Med. 2022 Dec; 2021 Dec 7. PMID: 34875947.
• Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, Lovly CM, Perlmutter J, Gray SW, Hwang J, Lieu C, André F, Azad N, Borad M, Tafe L, Messersmith H, Robson M, Meric-Bernstam F. J Clin Oncol. 2022 Apr 10; 2022 Feb 17. PMID: 35175857.
• Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas.Eder JP, Doroshow DB, Do KT, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. JCO Precis Oncol. 2021 Nov. PMID: 34994649.
• Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP. JCO Precis Oncol. 2021; 2021 Sep 7. PMID: 34527850.
• Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan.Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Lancet Oncol. 2021 Mar. PMID: 33662283.
• Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Zwiebel JA, Rubinstein LV, Little RF, Arteaga CL, Comis R, Abrams JS, O'Dwyer PJ, Conley BA. J Clin Oncol. 2020 Nov 20; 2020 Oct 13. PMID: 33048619.
• EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas.Maracaja DLV, Puthenpura V, Pels SG, O'Malley DP, Sklar JL, Finberg KE, Xu ML. Appl Immunohistochem Mol Morphol. 2020 Nov/Dec. PMID: 31789821.
• The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA. J Natl Cancer Inst. 2020 Oct 1. PMID: 31922567.
• Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testing.Hafez N, Walther Z, Eder JP, Sklar JL, Gettinger SN, Finberg KE, Goldberg SB. Lancet Oncol. 2020 Mar; 2020 Mar 2. PMID: 32950226.
• Somatic PRKAR1A mutation in sporadic atrial myxoma with cerebral parenchymal metastases: a case report.Roque A, Kimbrough T, Traner C, Baehring JM, Huttner A, Adams J, Canosa S, Sklar J, Madri JA. J Med Case Rep. 2019 Dec 25; 2019 Dec 25. PMID: 31874650.
• The Clinical Autopsy and Genomic Testing.Sklar J. Am J Pathol. 2019 Sep; 2019 Jun 11. PMID: 31199923.
• Presentation of Liver Failure From a Pericardial Mass.Nguyen VQ, Workman V, Stendahl K, Young L, Sklar J, Baldassarre LA. Circ Cardiovasc Imaging. 2019 Jun; 2019 Jun 6. PMID: 31167559.
• Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targets.Stewart T, Finberg K, Walther Z, Sklar JL, Hafez N, Eder JP, Anderson K, Wilson F, Goldberg SB. Lancet Oncol. 2018 Dec; 2018 Nov 28. PMID: 32956641.
• Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Lancet Oncol. 2018 Jan. PMID: 29304353.
• Introduction to the Yale Precision Medicine Tumor Board.Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Lancet Oncol. 2018 Jan. PMID: 29304351.
• EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.Cecchini M, Sklar J, Lacy J. J Natl Compr Canc Netw. 2017 Sep. PMID: 28874593.
• Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PM. J Mol Diagn. 2017 Mar; 2017 Feb 7. PMID: 28188106.
• The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis.Ma X, Wang J, Wang J, Ma CX, Gao X, Patriub V, Sklar JL. Oncotarget. 2017 Jan 17. PMID: 27845897.
• Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples.Jin W, Tang Q, Wan M, Cui K, Zhang Y, Ren G, Ni B, Sklar J, Przytycka TM, Childs R, Levens D, Zhao K. Nature. 2015 Dec 3. PMID: 26605532.
• A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process.Yuan H, Qin F, Movassagh M, Park H, Golden W, Xie Z, Zhang P, Sklar J, Li H. Cancer Discov. 2013 Dec; 2013 Oct 2. PMID: 24089019.
• Molecular tumor profiling for prediction of response to anticancer therapies.Walther Z, Sklar J. Cancer J. 2011 Mar-Apr. PMID: 21427550.
• Gene fusions and RNA trans-splicing in normal and neoplastic human cells.Li H, Wang J, Ma X, Sklar J. Cell Cycle. 2009 Jan 15; 2009 Jan 6. PMID: 19158498.
• A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells.Li H, Wang J, Mor G, Sklar J. Science. 2008 Sep 5. PMID: 18772439.
• Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival.Li H, Ma X, Wang J, Koontz J, Nucci M, Sklar J. Proc Natl Acad Sci U S A. 2007 Dec 11; 2007 Dec 6. PMID: 18077430.
• Absence of Y chromosome in human placental site trophoblastic tumor.Hui P, Wang HL, Chu P, Yang B, Huang J, Baergen RN, Sklar J, Yang XJ, Soslow RA. Mod Pathol. 2007 Oct; 2007 Jul 20. PMID: 17643092.
• Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes.Baehring JM, Hochberg FH, Betensky RA, Longtine J, Sklar J. J Neurol Sci. 2006 Sep 25; 2006 Jun 9. PMID: 16764890.
• Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors.Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H, Dal Cin P, Fletcher JA, Sklar J. Proc Natl Acad Sci U S A. 2001 May 22. PMID: 11371647.
• Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18.Morgan JA, Yin Y, Borowsky AD, Kuo F, Nourmand N, Koontz JI, Reynolds C, Soreng L, Griffin CA, Graeme-Cook F, Harris NL, Weisenburger D, Pinkus GS, Fletcher JA, Sklar J. Cancer Res. 1999 Dec 15. PMID: 10626814.
• Augmented expression of a human gene for 8-oxoguanine DNA glycosylase (MutM) in B lymphocytes of the dark zone in lymph node germinal centers.Kuo FC, Sklar J. J Exp Med. 1997 Nov 3. PMID: 9348312.
• Isolation and functional analysis of a cDNA for human Jagged2, a gene encoding a ligand for the Notch1 receptor.Luo B, Aster JC, Hasserjian RP, Kuo F, Sklar J. Mol Cell Biol. 1997 Oct. PMID: 9315665.
• Detection of mutations by cleavage of DNA heteroduplexes with bacteriophage resolvases.Mashal RD, Koontz J, Sklar J. Nat Genet. 1995 Feb. PMID: 7719346.
• TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J. Cell. 1991 Aug 23. PMID: 1831692.
• Rapid, nonradioactive detection of clonal T-cell receptor gene rearrangements in lymphoid neoplasms.Bourguin A, Tung R, Galili N, Sklar J. Proc Natl Acad Sci U S A. 1990 Nov. PMID: 2236063.
• T cell receptor gene trans-rearrangements: chimeric gamma-delta genes in normal lymphoid tissues.Tycko B, Palmer JD, Sklar J. Science. 1989 Sep 15. PMID: 2551037.
• Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease.Weiss LM, Movahed LA, Warnke RA, Sklar J. N Engl J Med. 1989 Feb 23. PMID: 2536894.
• Analysis of DNA surrounding the breakpoints of chromosomal translocations involving the beta T cell receptor gene in human lymphoblastic neoplasms.Reynolds TC, Smith SD, Sklar J. Cell. 1987 Jul 3. PMID: 3036364.
• Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation.Cleary ML, Smith SD, Sklar J. Cell. 1986 Oct 10. PMID: 2875799.
• Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma.Cleary ML, Meeker TC, Levy S, Lee E, Trela M, Sklar J, Levy R. Cell. 1986 Jan 17. PMID: 3079673.
• Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones.Cleary ML, Epstein MA, Finerty S, Dorfman RF, Bornkamm GW, Kirkwood JK, Morgan AJ, Sklar J. Science. 1985 May 10. PMID: 2986287.
• Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency.Shearer WT, Ritz J, Finegold MJ, Guerra IC, Rosenblatt HM, Lewis DE, Pollack MS, Taber LH, Sumaya CV, Grumet FC. N Engl J Med. 1985 May 2. PMID: 2984567.